Sarepta Therapeutics Inc (SRPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) has a cash flow conversion efficiency ratio of -0.135x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-202.68 Million) by net assets ($1.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Sarepta Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Sarepta Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Sarepta Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sarepta Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sarepta Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Melco Resorts & Entertainment Limited
F:MAS
|
0.355x |
|
Addus HomeCare Corporation
NASDAQ:ADUS
|
0.047x |
|
Wuxi Rural Commercial Bank Co Ltd
SHG:600908
|
-0.061x |
|
LandBridge Company LLC
NYSE:LB
|
0.051x |
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
0.100x |
|
BCO LATINOAMER.D.COM.EX.E
F:D8Q
|
0.125x |
|
Petrovietnam Power Corp
VN:POW
|
-0.080x |
|
Fibra Terrafina
MX:TERRA13
|
0.027x |
Annual Cash Flow Conversion Efficiency for Sarepta Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Sarepta Therapeutics Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Sarepta Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.14 Billion | $-205.48 Million | -0.180x | -33.74% |
| 2024-12-31 | $1.53 Billion | $-205.79 Million | -0.135x | +76.90% |
| 2023-12-31 | $859.34 Million | $-500.99 Million | -0.583x | +31.02% |
| 2022-12-31 | $384.95 Million | $-325.35 Million | -0.845x | -76.98% |
| 2021-12-31 | $928.01 Million | $-443.17 Million | -0.478x | -438.51% |
| 2020-12-31 | $761.76 Million | $107.47 Million | 0.141x | +125.29% |
| 2019-12-31 | $818.19 Million | $-456.46 Million | -0.558x | -48.18% |
| 2018-12-31 | $1.03 Billion | $-388.66 Million | -0.377x | -28.08% |
| 2017-12-31 | $789.22 Million | $-232.00 Million | -0.294x | +59.74% |
| 2016-12-31 | $336.69 Million | $-245.82 Million | -0.730x | +7.02% |
| 2015-12-31 | $190.35 Million | $-149.47 Million | -0.785x | -51.29% |
| 2014-12-31 | $247.65 Million | $-128.54 Million | -0.519x | -98.31% |
| 2013-12-31 | $247.19 Million | $-64.69 Million | -0.262x | -9.01% |
| 2012-12-31 | $123.68 Million | $-29.69 Million | -0.240x | +68.55% |
| 2011-12-31 | $31.02 Million | $-23.68 Million | -0.763x | -114.14% |
| 2010-12-31 | $-2.82 Million | $-15.21 Million | 5.399x | +1549.76% |
| 2009-12-31 | $23.63 Million | $-8.80 Million | -0.372x | +52.52% |
| 2008-12-31 | $15.73 Million | $-12.34 Million | -0.784x | +16.15% |
| 2007-12-31 | $26.38 Million | $-24.68 Million | -0.935x | -71.13% |
| 2006-12-31 | $37.71 Million | $-20.61 Million | -0.547x | -99.95% |
| 2005-12-31 | $53.66 Million | $-14.67 Million | -0.273x | +69.80% |
| 2004-12-31 | $26.27 Million | $-23.78 Million | -0.905x | -124.74% |
| 2003-12-31 | $43.39 Million | $-17.48 Million | -0.403x | +53.32% |
| 2002-12-31 | $23.48 Million | $-20.26 Million | -0.863x | -105.49% |
| 2001-12-31 | $30.53 Million | $-12.82 Million | -0.420x | -53.48% |
| 2000-12-31 | $33.37 Million | $-9.13 Million | -0.274x | +57.16% |
| 1999-12-31 | $11.90 Million | $-7.60 Million | -0.639x | +14.21% |
| 1998-12-31 | $9.00 Million | $-6.70 Million | -0.744x | -354.11% |
| 1997-12-31 | $18.30 Million | $-3.00 Million | -0.164x | +91.80% |
| 1996-12-31 | $800.00K | $-1.60 Million | -2.000x | -124.72% |
| 1995-12-31 | $2.00 Million | $-1.78 Million | -0.890x | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 ski… Read more